Trials / Terminated

TerminatedNCT00040131

Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

Status: Terminated
Phase: Phase 2
Study type: Interventional
Enrollment: 316 (actual)

Sponsor: Merck Sharp & Dohme LLC · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.

Conditions

Bile Duct Diseases
Biliary Tract Diseases
Gallbladder Diseases
Pancreatitis
Pancreatic Diseases

Interventions

Type	Name	Description
DRUG	IL-10

Timeline

Start date: 2002-01-01
Primary completion: 2002-12-01
Completion: 2003-01-01
First posted: 2002-06-21
Last updated: 2015-11-02

Source: ClinicalTrials.gov record NCT00040131. Inclusion in this directory is not an endorsement.